摘要
目的:分析采取尼妥珠单抗同步放疗方案治疗非小细胞肺癌脑转移的临床价值。方法:2016年1月-2019年1月收治非小细胞肺癌脑转移患者60例,随机分为两组。对照组单纯采取放疗方案,观察组采用放疗方案联合运用尼妥珠单抗治疗,比较两组治疗效果。结果:观察组客观缓解率及疾病控制率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:采取尼妥珠单抗同步放疗方案治疗非小细胞肺癌脑转移患者效果理想,且安全性相对较高。
Objective:To explore the clinical value of nimotuzumab simultaneous radiotherapy in the treatment of brain metastasis of non-small cell lung cancer.Methods:From January 2016 to January 2019,60 patients with brain metastasis from non-small cell lung cancer were selected and randomly divided into two groups.The control group was treated with radiotherapy,and the observation group was treated with radiotherapy combined with nitzumab.We compared the efficacy of the two groups.Results:The objective remission rate and disease control rate in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between groups(P>0.05).Conclusion:The clinical value of nimotuzumab simultaneous radiotherapy in the treatment of brain metastasis of non-small cell lung cancer was better,and the security was relatively high.
作者
黄勇
彭勇
崔建华
Huang Yong;Peng Yong;Cui Jianhua(The People's Hospital of Ningxiang City,Hunan,Ningxiang 410600)
出处
《中国社区医师》
2019年第36期60-61,共2页
Chinese Community Doctors
关键词
非小细胞肺癌
脑转移
尼妥珠单抗
放疗
Non-small cell lung cancer
Brain metastasis
Nimotuzumab
Radiotherapy
